Comparative Pharmacology
Head-to-head clinical analysis: CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER versus CEFZIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER versus CEFZIL.
CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER vs CEFZIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefotetan is a cephamycin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), resulting in cell lysis and death.
Cefprozil inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting peptidoglycan cross-linking.
1 to 2 g intravenously every 12 hours for 5 to 10 days. For severe infections, 2 g intravenously every 12 hours.
500 mg orally twice daily for 10 days; for uncomplicated skin infections, 250 mg twice daily or 500 mg once daily.
None Documented
None Documented
Terminal elimination half-life 3-4 hours in normal renal function; prolonged in renal impairment (e.g., up to 13 hours in severe renal failure).
1.2-1.5 hours in healthy adults; prolonged in renal impairment (e.g., up to 6-8 hours in severe renal failure)
Primarily renal (unchanged drug) ~88%; minor biliary/fecal ~6-9%.
Renal: 80-91% unchanged in urine; biliary/fecal: minimal (<5%)
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic